HK1206339A1 - N-aryltriazole compounds as lpar antagonists - Google Patents

N-aryltriazole compounds as lpar antagonists Download PDF

Info

Publication number
HK1206339A1
HK1206339A1 HK15106924.1A HK15106924A HK1206339A1 HK 1206339 A1 HK1206339 A1 HK 1206339A1 HK 15106924 A HK15106924 A HK 15106924A HK 1206339 A1 HK1206339 A1 HK 1206339A1
Authority
HK
Hong Kong
Prior art keywords
phenyl
methyl
triazol
biphenyl
hydrogen
Prior art date
Application number
HK15106924.1A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬．迪姆斯．加布里埃爾
斯蒂芬．迪姆斯．加布里埃尔
馬修．邁克爾．漢密爾頓
马修．迈克尔．汉密尔顿
錢義民
钱义民
阿奇尤特哈拉.西杜瑞
Original Assignee
霍夫曼-拉罗奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1206339(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉罗奇有限公司 filed Critical 霍夫曼-拉罗奇有限公司
Publication of HK1206339A1 publication Critical patent/HK1206339A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106924.1A 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists HK1206339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661953P 2012-06-20 2012-06-20
US61/661,953 2012-06-20
PCT/EP2013/062463 WO2013189865A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
HK1206339A1 true HK1206339A1 (en) 2016-01-08

Family

ID=48628669

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106924.1A HK1206339A1 (en) 2012-06-20 2013-06-17 N-aryltriazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US20150133512A1 (cs)
EP (1) EP2864301A1 (cs)
JP (1) JP2015520203A (cs)
KR (1) KR20150011389A (cs)
CN (1) CN104395299A (cs)
AU (1) AU2013279513A1 (cs)
BR (1) BR112014030674A2 (cs)
CA (1) CA2869564A1 (cs)
CL (1) CL2014003241A1 (cs)
CO (1) CO7131357A2 (cs)
EA (1) EA201492281A1 (cs)
HK (1) HK1206339A1 (cs)
IL (1) IL236087A0 (cs)
IN (1) IN2014DN09352A (cs)
MA (1) MA37762B1 (cs)
MX (1) MX2014014711A (cs)
PE (1) PE20142305A1 (cs)
PH (1) PH12014502363A1 (cs)
SG (1) SG11201407228PA (cs)
UA (1) UA110310C2 (cs)
WO (1) WO2013189865A1 (cs)
ZA (1) ZA201408167B (cs)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014003499A2 (pt) 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
TW201437200A (zh) * 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
EA033923B1 (ru) 2013-03-15 2019-12-10 Эпиджен Байосайенсиз, Инк. Гетероциклические соединения, применимые в лечении заболеваний
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
RU2689315C2 (ru) 2014-06-27 2019-05-27 Убе Индастриз, Лтд. Соль гетероциклического соединения, замещенного галогеном
WO2017055316A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
WO2017055313A1 (en) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Amido-substituted azole compounds
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2018078009A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives
WO2018078005A1 (en) 2016-10-29 2018-05-03 Bayer Pharma Aktiengesellschaft Amido-substituted azaspiro derivatives as tankyrase inhibitors
WO2018087126A1 (en) 2016-11-09 2018-05-17 Bayer Pharma Aktiengesellschaft Amido-substituted cyclohexane derivatives as inhibitors of tankyrase
CN107827829A (zh) * 2017-11-07 2018-03-23 大连理工大学 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法
CN107721984A (zh) * 2017-11-07 2018-02-23 大连理工大学 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法
WO2019126086A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azines as lpa antagonists
CA3085561A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid triazole azines as lpa antagonists
WO2019126085A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
US11261174B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Pyrazole O-linked carbamoyl cyclohexyl acids as LPA antagonists
WO2019126089A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid pyrazole azines as lpa antagonists
JP7212047B2 (ja) 2017-12-19 2023-01-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
US11261180B2 (en) 2017-12-19 2022-03-01 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as LPA antagonists
TW201927778A (zh) 2017-12-19 2019-07-16 美商必治妥美雅史谷比公司 作為lpa拮抗劑之環己基酸三唑唑類
CN112041304B (zh) 2017-12-19 2025-03-07 百时美施贵宝公司 作为lpa拮抗剂的异噁唑n-连接的氨基甲酰基环己基酸
WO2019126084A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
EP3852746B1 (en) 2018-09-18 2023-03-29 Bristol-Myers Squibb Company Cyclopentyl acids as lpa antagonists
ES2941774T3 (es) 2018-09-18 2023-05-25 Bristol Myers Squibb Co Acidos oxabiciclo como antagonistas de LPA
CN111434653A (zh) * 2019-01-15 2020-07-21 武汉朗来科技发展有限公司 三氮唑类化合物及其制备方法与用途
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4337641A1 (en) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7709612B2 (ja) 2021-12-08 2025-07-16 ギリアード サイエンシーズ， インコーポレイテッド Ｌｐａ受容体アンタゴニスト及びそれらの使用
CN115745848A (zh) * 2022-12-07 2023-03-07 上海优合生物科技有限公司 一种氨基胍的加工合成工艺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
EA201390821A1 (ru) * 2010-12-07 2013-10-30 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты и их применение
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
BR112014003499A2 (pt) * 2011-08-15 2017-06-13 Intermune Inc compostos ou sais farmaceuticamente aceitáveis dos mesmos e composições farmacêuticas e respectivos usos de quantidades eficazes e métodos para tratar, prevenir, reverter, parar ou retardar a prograssão de doença ou condição selecionada de fibrose, câncer ou distúrbios respiratórios e modular a atividade de receptor em célula
AU2013279512A1 (en) * 2012-06-20 2014-10-16 F. Hoffmann-La Roche Ag N-alkyltriazole compounds as LPAR antagonists

Also Published As

Publication number Publication date
IL236087A0 (en) 2015-02-01
EP2864301A1 (en) 2015-04-29
MA37762B1 (fr) 2018-04-30
AU2013279513A1 (en) 2014-10-16
PH12014502363A1 (en) 2015-01-12
CN104395299A (zh) 2015-03-04
ZA201408167B (en) 2015-12-23
JP2015520203A (ja) 2015-07-16
UA110310C2 (uk) 2015-12-10
US20150133512A1 (en) 2015-05-14
IN2014DN09352A (cs) 2015-07-17
KR20150011389A (ko) 2015-01-30
MX2014014711A (es) 2015-03-04
EA201492281A1 (ru) 2015-04-30
BR112014030674A2 (pt) 2017-06-27
CO7131357A2 (es) 2014-12-01
WO2013189865A1 (en) 2013-12-27
PE20142305A1 (es) 2015-01-16
MA37762A1 (fr) 2017-07-31
SG11201407228PA (en) 2014-12-30
CL2014003241A1 (es) 2015-03-20
CA2869564A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
HK1206339A1 (en) N-aryltriazole compounds as lpar antagonists
TWI635083B (zh) １，４－雙取代嗒類似物及運動神經元存活（ｓｍｎ）缺乏相關病況之治療方式
TW419471B (en) Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same
US9321738B2 (en) N-alkyltriazole compounds as LPAR antagonists
TWI606039B (zh) Ａｐｊ受體之三唑激動劑
EP1685113B1 (en) Substituted pyrazoles as ppar agonists
CN104395309B (zh) 环状桥头醚dgat1抑制剂
JP2016519674A (ja) 過剰増殖障害を治療または予防するための３−アセチルアミノ−１−（フェニル−ヘテロアリール−アミノカルボニルまたはフェニル−ヘテロアリール−カルボニルアミノ）ベンゼン誘導体
AU2009240856A1 (en) Substituted pyrazoles, compositions containing such compounds and methods of use
CN104411690A (zh) 作为lpar拮抗剂的取代的吡唑化合物
WO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
TW201443046A (zh) 噻二唑類似物及治療ｓｍｎ缺乏相關症狀之方法
TWI592407B (zh) 飢餓素ｏ－醯基轉移酶抑制劑
CN113727973A (zh) 可用作类法尼醇x受体调节剂的取代酰胺化合物
US9493430B2 (en) Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN106604918B (zh) 多环hERG激活剂
TW201625613A (zh) 作為生長激素釋放肽受體激動劑之四氫吡唑並吡啶衍生物
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
TW201617314A (zh) 羧酸衍生物
UA48157C2 (uk) Мономери 4,4-(двозаміщених)циклогексан-1-олів, фармацевтична композиція та спосіб лікування астми
CN117043157A (zh) Erap抑制剂